A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

被引：0

作者：

Cortes, Jorge E. ^{[1
]}

Perl, Alexander E. ^{[2
]}

Smith, Catherine C. ^{[3
]}

Kovacsovics, Tibor ^{[4
]}

Dombret, Herve ^{[5
]}

Dohner, Hartmut ^{[6
]}

Steffen, Bjorn ^{[7
]}

Pigneux, Arnaud ^{[8
]}

Rousselot, Philippe ^{[9
]}

Krauter, Juergen ^{[10
]}

Martinelli, Giovanni ^{[11
]}

Estey, Elihu H. ^{[12
]}

Burnett, Alan K. ^{[13
]}

Ho, Anthony D. ^{[14
]}

Ifrah, Norbert ^{[15
]}

de Witt, Theo ^{[16
]}

Corringham, Robert ^{[17
]}

James, Joyce ^{[17
]}

Lilienfeld, David ^{[17
]}

Leo, Eugen ^{[17
]}

Gammon, Guy ^{[17
]}

Levis, Mark J. ^{[18
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[5] Univ Paris 07, Hop St Louis, AP HP, EA 3518, Paris, France

[6] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany

[7] Klinikum JW Goethe Univ Frankfurt Main, Frankfurt, Germany

[8] CHU Bordeaux, Pessac, France

[9] Univ Versailles St Quentin Yvelines, Hop Versailles, Le Chesnay, France

[10] Hannover Med Sch, D-3000 Hannover, Germany

[11] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[12] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[13] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales

[14] Univ Heidelberg, Dept Hematol & Oncol, Heidelberg, Germany

[15] CHU Angers, Serv Hematol, Angers, France

[16] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[17] Ambit Biosci, San Diego, CA USA

[18] Johns Hopkins Univ, Div Hematol Malignancies, Dept Oncol, Baltimore, MD USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1105 / 1105

页数：1

共 50 条

[1] QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD(+) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY
Russell, N.
Tallman, M. S.
Goldberg, S.
Perl, A. E.
Marie, J. P.
Martinelli, G.
Larson, R. A.
Schiller, G.
Trone, D.
Gammon, G.
Levis, M.
Cortes, J. E.
HAEMATOLOGICA, 2014, 99 : 36 - 36
[2] Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia
Cortes, Jorge E.
Perl, Alexander E.
Dombret, Herve
Kayser, Sabine
Steffen, Bjoern
Rousselot, Philippe
Martinelli, Giovanni
Estey, Elihu H.
Burnett, Alan K.
Gammon, Guy
Trone, Denise
Leo, Eugen
Levis, Mark J.
BLOOD, 2012, 120 (21)
[3] Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)
Cortes, Jorge E.
Tallman, Martin S.
Schiller, Gary
Trone, Denise
Gammon, Guy
Goldberg, Stuart
Perl, Alexander E.
Marie, Jean Pierre
Martinelli, Giovanni
Levis, Mark
BLOOD, 2013, 122 (21)
[4] Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
Takeshi Takahashi
Kensuke Usuki
Kosei Matsue
Hitoshi Ohno
Toru Sakura
Ryota Imanaka
Masato Murakami
Shoichi Ohwada
Taiga Takagi
Sakura Sakajiri
International Journal of Hematology, 2019, 110 : 665 - 674
[5] Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
Takahashi, Takeshi
Usuki, Kensuke
Matsue, Kosei
Ohno, Hitoshi
Sakura, Toru
Imanaka, Ryota
Murakami, Masato
Ohwada, Shoichi
Takagi, Taiga
Sakajiri, Sakura
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 665 - 674
[6] Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).
Perl, Alexander E.
Dohner, Hartmut
Rousselot, Philippe H.
Marie, Jean-Pierre
Martinelli, Giovanni
Shah, Neil P.
Levis, Mark J.
Gammon, Guy
Trone, Denise
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.
Schiller, Gary J.
Tallman, Martin S.
Goldberg, Stuart L.
Perl, Alexander E.
Marie, Jean-Pierre
Martinelli, Giovanni
Larson, Richard A.
Russell, Nigel
Trone, Denise
Gammon, Guy
Levis, Mark J.
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[8] TREATMENT WITH QUIZARTINIB (AC220) ENABLES A HIGH RATE OF PATIENTS WITH RELAPSED OR REFRACTORY FLT3-ITD(+) ACUTE MYELOID LEUKEMIA TO BE BRIDGED TO HSCT
Martinelli, G.
Levis, M. J.
Perl, A. E.
Dombret, H.
Steffen, B.
Rousselot, P.
Estey, E. H.
Shah, N. P.
Gammon, G.
Trone, D.
Cortes, J. E.
HAEMATOLOGICA, 2014, 99 : 35 - 35
[9] EFFICACY AND SAFETY OF QUIZARTINIB (AC220) IN PATIENTS AGE ≥60 YEARS WITH FLT3-ITD-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Doehner, H.
Perl, A.
Rousselot, P.
Marie, J.
Martinelli, G.
Gammon, G.
Trone, D.
Cortes, J.
Levis, M.
HAEMATOLOGICA, 2013, 98 : 233 - 233
[10] Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.
Martinelli, Giovanni
Perl, Alexander E.
Dombret, Herve
Kayser, Sabine
Steffen, Bjoern
Rousselot, Philippe H.
Estey, Elihu
Burnett, Alan K.
Shah, Neil P.
Gammon, Guy
Trone, Denise
Levis, Mark J.
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →